The multi-center clinical study will investigate the combination of Sofosbuvir and Ribavirin in children between ages 3 and 17. The combined drug therapy has shown 90 percent to 100 percent cure rate in adult patients, according to the report. Dr. Teckman hopes to discover similar results in pediatric patients.
“A lot of times studies for children don’t get approved. The exciting part with our study is that the medication has already been tested in adults, and we are moving rapidly to test in children,” said Dr. Teckman.
More articles on gastroenterology:
Drug therapy for celiac disease?
FDA grants tentative approval of UCERIS for ulcerative colitis
Antidepressants may increase GI bleeding risk
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.